The effect of mibefradil on ischemic episodes with and without increase in heart rate

Cardiovascular Drugs and Therapy

Volumn 14, Issue 5, 2000, Pages 503-509

  Tzivoni, Dan ^a   Gilula, Zvi ^b   Klutstein, Marc W ^a   Reisin, Leonardo ^c   Botvin, Shulamit ^d   Kobrin, Isaac ^e  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c Barzilai Hospital   (Israel)

^d KAPLAN HOSPITAL   (Israel)

^e F Hoffmann LaRoche ^*  (Israel)

Author keywords

Ambulatory ECG monitoring; Coronary tone; Mibefradil; Myocardial ischemia; Silent ischemia; T channel calcium antagonist

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; MIBEFRADIL;

ADULT; AGED; AMBULATORY MONITORING; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG MECHANISM; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; VASODILATATION;

ANGINA PECTORIS; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HUMANS; MALE; MIBEFRADIL; MIDDLE AGED; MYOCARDIAL ISCHEMIA;

EID: 0033786082     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007889006370     Document Type: Article

References (39)

1. Myocardialischemia during daily activities and stress
2. Change in myocardial ischemic threshold during daily activities
3. Subsets of ambulatory myocardial ischemia based on heart rate activity; circadian distribution and response to anti-ischemic medication
4. Pathophysiology of silent myocardial ischemia during daily life
5. Role of increases in heart rate in determining the occurrence and frequency of myocardial ischemia during daily life in patients with stable coronary artery disease
6. Myocardial ischemia during daily activities: The importance of increased myocardial oxygen demand
7. Transient myocardial ischemia in patients with chronic angina: Relation to heart rate changes and variability in exercise threshold. BAY r 1999 in Chronic Angina Study Group
8. Comparison of propranolol, diltiazem and nifedipine in the treatment of ambulatory ischemia in patients with stable angina: Differential effects on ambulatory ischemia, exercise performance and anginal symptoms
9. Effects of Ro-405967, a novel calcium antagonist, on myocardial function during ischemia by lowering coronary perfusion pressure in dogs: Comparison with verapamil
10. 2+ channels by Ro 40-5967
11. Ro 40-5967: A new nondihydropyridine calcium antagonist
12. Hemodynamic and humoral effect of the novel calcium antagonist Ro-5967 in patients with hypertension
13. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts
14. MACH-I Investigators. The design of the mortality assessment in congestive heart failure trial (MACH-1, Mibefradil)
15. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967)
16. Mibefradil in the treatment of systemic hypertension: Comparative studies with other calcium antagonists
17. Antihypertensive effects of mibefradil in the treatment of mild to moderate systemic hypertension
18. A randomized, double-blind trial comparing mibefradil and amlodipine: Two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group
19. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study
20. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on silent ischemia in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study
21. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris
22. Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectorals
23. Treatment of chronic angina pectoris with combination mibefradil and β blocker therapy
24. Adding the new calcium antagonist mibefradil to patients receiving long-term β blocker therapy results in improved antianginal and antiischemic therapy
25. Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: A multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release Diltiazem
26. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction
27. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure
28. Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia: Results of a multicenter, placebo-controlled trial
29. Potent vasodilatory with minor cardiode-pressent actions of mibefradil in human cardiac tissue
30. Effect of metoprolol in reducing myocardial ischemic threshold during exercise and during daily activity
31. Comparison between metoprolol OROS given once daily and metoprolol twice or thrice daily in suppressing exercise induced and daily myocardial ischemia
32. Effect of diltiazem on symptomatic and asymptomatic episodes of ST segment depression occurring during daily life and during exercise
33. Efficacy of metoprolol and diltiazem in treating silent myocardial ischemia
34. Paradoxical effect of long-term treatment of nifedipine on total ischemic load in patients with stable angina pectoris
35. Optimal control of myocardial ischemia: The benefit of a fixed combination of atenolol and nifedipine in patients with chronic stable angina
36. Usefulness of severity of myocardial ischemia on exercise testing in predicting the severity of myocardial ischemia during daily activities
37. Attenuation of circadian variation by combined antianginal therapy with suppression of morning and evening increases in transient myocardial ischemia
38. Withdrawal of Posicor from market
39. What lessons can be learnt from withdrawal of mibefradil from the market?